PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ$1.26
Market Cap
$65.44M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
782 of 924
Rank in Industry
440 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
PMVP Insider Trading Activity
PMVP Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $15,200 | 2 | 100 |
Related Transactions
| Carulli Michael | Chief Financial Officer | 0 | $0 | 1 | $4,347 | $-4,347 |
| Jalota Deepika | Chief Development Officer | 0 | $0 | 1 | $10,853 | $-10,853 |
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and …
Insider Activity of PMV Pharmaceuticals, Inc.
Over the last 12 months, insiders at PMV Pharmaceuticals, Inc. have bought $0 and sold $15,200 worth of PMV Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at PMV Pharmaceuticals, Inc. have bought $106.6M and sold $18.57M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,900,000 shares for transaction amount of $34.2M was made by RA CAPITAL MANAGEMENT, L.P. (10 percent owner) on 2020‑09‑29.
List of Insider Buy and Sell Transactions, PMV Pharmaceuticals, Inc.
| 2024-09-11 | Sale | Jalota Deepika | Chief Development Officer | 7,218 0.0141% | $1.50 | $10,853 | -0.66% | |
| 2024-09-11 | Sale | Carulli Michael | Chief Financial Officer | 2,891 0.0057% | $1.50 | $4,347 | -0.66% | |
| 2023-11-22 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 87,786 0.1816% | $2.23 | $195,763 | -25.56% | |
| 2023-09-15 | Sale | Alland Leila | Chief Medical Officer | 6,291 0.0128% | $6.62 | $41,646 | -74.14% | |
| 2023-09-15 | Sale | Jalota Deepika | Chief Development Officer | 4,104 0.0084% | $6.62 | $27,168 | -74.14% | |
| 2022-05-26 | Sale | OrbiMed Genesis GP LLC | 26,253 0.0695% | $15.93 | $418,210 | -25.36% | ||
| 2022-03-29 | Sale | ORBIMED CAPITAL LLC | 365,000 0.7867% | $21.52 | $7.85M | -45.86% | ||
| 2021-10-06 | Sale | Schroeder Thilo | director | 800 0.0019% | $30.15 | $24,120 | -43.26% | |
| 2021-10-04 | Sale | Schroeder Thilo | director | 100 0.0002% | $30.08 | $3,008 | -43.75% | |
| 2021-10-01 | Sale | Schroeder Thilo | director | 11,541 0.0255% | $30.10 | $347,384 | -46.13% | |
| 2021-09-30 | Sale | Schroeder Thilo | director | 2,978 0.0066% | $30.03 | $89,429 | -45.30% | |
| 2021-09-29 | Sale | Schroeder Thilo | director | 5,708 0.0127% | $30.04 | $171,468 | -45.33% | |
| 2021-09-27 | Sale | Schroeder Thilo | director | 1,753 0.004% | $30.11 | $52,783 | -44.51% | |
| 2021-09-22 | Sale | Schroeder Thilo | director | 100 0.0002% | $30.00 | $3,000 | -41.71% | |
| 2021-09-22 | Sale | LEVINE ARNOLD J | director | 3,500 0.0082% | $30.00 | $105,000 | -41.71% | |
| 2021-09-17 | Sale | Schroeder Thilo | director | 711 0.0016% | $30.03 | $21,351 | -42.79% | |
| 2021-09-13 | Sale | Schroeder Thilo | director | 13,272 0.0311% | $30.20 | $400,814 | -40.29% | |
| 2021-09-10 | Sale | Schroeder Thilo | director | 43,227 0.0948% | $30.51 | $1.32M | -44.58% | |
| 2021-09-09 | Sale | Schroeder Thilo | director | 14,329 0.0332% | $30.31 | $434,312 | -40.96% | |
| 2021-09-09 | Sale | Alland Leila | Chief Medical Officer | 100 0.0002% | $30.25 | $3,025 | -40.96% |
Total: 104
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 1710265 3.2932% | $2.15M | 1 | 0 | <0.0001% |
| Boxer Capital, LLC | 950000 1.8293% | $1.2M | 1 | 0 | <0.0001% | |
| Thompson Peter A. | 475000 0.9146% | $598,500.00 | 1 | 0 | <0.0001% | |
| ORONSKY ARNOLD L | 55555 0.107% | $69,999.30 | 1 | 0 | <0.0001% | |
| INTERWEST PARTNERS X LP | director | 55555 0.107% | $69,999.30 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$2,942,496 | 100 | 17.32% | $66.91M | |
$542,300 | 40 | -14.44% | $67.8M | |
$6,787,959 | 35 | 49.84% | $60.62M | |
$22,110,933 | 34 | 30.18% | $67.48M | |
$459,011,221 | 33 | 33.04% | $57.94M |
PMVP Institutional Investors: Active Positions
| Increased Positions | 21 | +20% | 4M | +9.17% |
| Decreased Positions | 43 | -40.95% | 4M | -10.34% |
| New Positions | 6 | New | 1M | New |
| Sold Out Positions | 12 | Sold Out | 2M | Sold Out |
| Total Postitions | 83 | -20.95% | 39M | -1.17% |
PMVP Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Orbimed Advisors Llc | $8,871.00 | 12.45% | 6.48M | 0 | 0% | 2024-12-31 |
| Sio Capital Management, Llc | $4,894.00 | 6.87% | 3.57M | +357,928 | +11.14% | 2024-12-31 |
| Arrowmark Colorado Holdings Llc | $4,807.00 | 6.75% | 3.51M | -138,840 | -3.81% | 2024-12-31 |
| Bml Capital Management, Llc | $4,749.00 | 6.67% | 3.47M | +2M | +105.28% | 2024-12-31 |
| Euclidean Capital Llc | $3,600.00 | 5.05% | 2.63M | 0 | 0% | 2024-12-31 |
| Alkeon Capital Management Llc | $3,211.00 | 4.51% | 2.34M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $2,936.00 | 4.12% | 2.14M | -137,701 | -6.04% | 2024-12-31 |
| Pfm Health Sciences, Lp | $2,849.00 | 4% | 2.08M | +68,205 | +3.39% | 2024-12-31 |
| Acadian Asset Management Llc | $2,848.00 | 4% | 2.08M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $1,571.00 | 2.21% | 1.15M | +1,687 | +0.15% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.